Plain-English translation of NCT05720130 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called [²¹²Pb]Pb-ADVC001, which is a type of targeted radiation therapy designed to treat advanced prostate cancer. The study has two main parts: first, doctors will carefully increase doses to find the safest and most effective dose, and then they will test that dose in larger groups of patients with different types of advanced prostate cancer.
Men with advanced prostate cancer often run out of treatment options as their cancer becomes resistant to standard medicines. This medication offers a new approach by using targeted radiation to attack cancer cells while potentially sparing healthy tissue, giving patients another treatment choice.
You likely qualify if…
You likely don't qualify if…
Participants will receive the medication by injection on a schedule that depends on which group they're in — either once weekly, every other week, every 4 weeks, or every 6 weeks. During the first phase, doctors will carefully increase doses in small groups to find the safest amount; in the second phase, larger groups will receive the selected dose to test how well it works. You'll have regular blood tests, imaging scans, and follow-up visits to monitor how you're responding and check for any side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Australia